+
Thank you!
Your submission has been received. We are sending the pitch to your email.
Oops! Something went wrong while submitting the form.

A Biological Gamechanger in Cancer Immunotherapy

CD4 T-cells reprogrammed to kill cancer — a Nordic innovation in IT and immunology

Get Investor Presentation
<subject>[background image] image of robotics lab (for a robotics and automation)</subject>
Lab
proof
100% response
Mouse trials
July 2025, 55 mice
IND preparation
Proof of concept
HLA-sequencing
AI platform convergence

About Catavax

Catavax develops the world's first immunotherapy that makes CD4 T cells toxic enough to kill cancer — a biological gamechanger based on IT and immunology.

Problem → Solution

Problem

CD8 focus, immune evasion, poor personalization

Solution

CD4 cytotoxic activation + bioinformatic targeting

Market & Business

$130B+ immunotherapy market (CAGR 13%)

Licensing model + pipeline development

Applicability across cancer types

Competitive edge: CD4 untapped potential

Team

Advisory Board

[headshot] image of customer (for a real estate tech)
Morten Nielsen
Professor at DTU
LinkedIn
[headshot] image of customer (for a construction company)
Peter Johannes Holst
Professor at KU
LinkedIn
[headshot] image of customer (for a bars & pub)
A. Kaare Nørgaard
M.Sc.E.E., MBA
LinkedIn

Management team

[headshot] image of customer (for a real estate tech)
A. Kaare Nørgaard
CEO
LinkedIn
[headshot] image of customer (for a construction company)
Christian Drejøe
President
LinkedIn
[headshot] image of customer (for a bars & pub)
Søren Tang Hansen
Vice President
LinkedIn
[headshot] image of customer (for a bars & pub)
Jens Hagenau
Member of the Board
LinkedIn
[headshot] image of customer (for an auto dealership)
Henrik Ibsen
Business Development
LinkedIn

Pharmaceutical team

[headshot] image of customer (for a real estate tech)
Caspar Skovbo Christensen
Research Scientist
LinkedIn
[headshot] image of customer (for a construction company)
Linh Trinh
Research Scientist
LinkedIn
[headshot] image of customer (for a bars & pub)
Caroline Larsen
Research Scientist
LinkedIn
[headshot] image of customer (for an auto dealership)
Haakon Nørgaard
Data analyst
LinkedIn

Latest News

News

Catavax founded

November 2, 2024
We have founded Catavax A/S in DK and US. Capital raised, patent applications submitted, pre-clinical trials started. We wish to find one or a significant part of a cure for cancer, utilizing the immune system.
Partners
News

Ready for pre-clinical testing

March 26, 2025
Curing cancer (?) Soon we will start pre-clinical testing to see if we are right in our assumption on how the immune system functions - so that we can harness it to kill cancer. In the picture are (from left to right): Linh (who is responsible for the tests carried out by Hervolution), Kaare (CEO of Catavax), Peter (Founder of Hervolution), and Christian (chairman of Catavax)
Partners
News

Pre-clinical test started

May 20, 2025
We have just started our pre-clinical tests, that will show if the immune system has a response that under special conditions that we create will kill the cancer. To the right is Linh (in charge of the trial), to the left is Caroline.
Partners
News

First pre-clinical tests finished with remarkable success

July 7, 2023
We have finished the first pre-clinical trials with interesting data from the lab (human blood samples and our test vaccine). Now it is time to start animal trials. One step closer to curing (some major) cancers.
Partners
News

Staff expansion

September 3, 2025
TEAM NEWS: After a successful preclinical test, which brings us one step closer to curing cancer, we have expanded our staff with Linh Trinh and Caspar Skovbo Christensen
Partners

Investor

Secure, exclusive access.

Access confidential updates, milestones, and investor materials. Stay informed on our progress in next-generation cancer immunotherapy.

Get Investor Presentation
image of ai-enhanced lab equipment organizing genetic samples for an ai biotech company
image of biotech research process for ai biotech company